Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 269

1.

Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer.

Nakai Y, Tanaka N, Asakawa I, Torimoto K, Miyake M, Anai S, Fujii T, Hasegawa M, Fujimoto K.

J Contemp Brachytherapy. 2019 Oct;11(5):409-416. doi: 10.5114/jcb.2019.88142. Epub 2019 Oct 30.

2.

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.

Nishiyama H, Yamamoto Y, Sassa N, Nishimura K, Fujimoto K, Fukasawa S, Yokoyama M, Enokida H, Takahashi K, Tanaka Y, Imai K, Shimamoto T, Perini R, Frenkl T, Bajorin D, Bellmunt J.

Int J Clin Oncol. 2019 Nov 15. doi: 10.1007/s10147-019-01545-4. [Epub ahead of print]

PMID:
31729625
3.

Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone.

Nakai Y, Tanaka N, Asakawa I, Anai S, Miyake M, Morizawa Y, Hori S, Owari T, Fujii T, Yamaki K, Hasegawa M, Fujimoto K.

Jpn J Clin Oncol. 2019 Oct 28. pii: hyz136. doi: 10.1093/jjco/hyz136. [Epub ahead of print]

PMID:
31665354
4.

Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged "no-problems".

Murasawa H, Sugiyama T, Matsuoka Y, Okabe T, Wakumoto Y, Tanaka N, Sugimoto M, Oyama M, Fujimoto K, Horie S, Funagoshi M, Arakawa I, Noto S, Shimozuma K.

Qual Life Res. 2019 Oct 3. doi: 10.1007/s11136-019-02316-4. [Epub ahead of print]

PMID:
31583618
5.

Lack of evidence regarding bone metastases of genitourinary cancers: interventions by surgery, radiotherapy, and bone-targeted systemic therapy.

Miyake M, Owari T, Fujimoto K.

Ann Transl Med. 2019 Jul;7(Suppl 3):S92. doi: 10.21037/atm.2019.04.52. No abstract available.

6.

Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan.

Tanaka N, Asakawa I, Hasegawa M, Fujimoto K.

Int J Urol. 2019 Sep 24. doi: 10.1111/iju.14098. [Epub ahead of print] Review.

PMID:
31549770
7.

A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future 'MRI-PDD Fusion TURBT'.

Miyake M, Maesaka F, Marugami N, Miyamoto T, Nakai Y, Ohnishi S, Gotoh D, Owari T, Hori S, Morizawa Y, Itami Y, Inoue T, Anai S, Torimoto K, Fujii T, Shimada K, Tanaka N, Fujimoto K.

Diagnostics (Basel). 2019 Sep 4;9(3). pii: E112. doi: 10.3390/diagnostics9030112.

8.

Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder.

Shiota T, Torimoto K, Okuda M, Iwata R, Kumamoto H, Miyake M, Hirayama A, Tanaka N, Fujimoto K.

Low Urin Tract Symptoms. 2019 Aug 28. doi: 10.1111/luts.12285. [Epub ahead of print]

PMID:
31460706
9.

Urinary nerve growth factor can predict therapeutic efficacy in children with monosymptomatic nocturnal enuresis.

Morizawa Y, Aoki K, Iemura Y, Hori S, Gotoh D, Fukui S, Nakai Y, Miyake M, Torimoto K, Tanaka N, Fujimoto K.

Neurourol Urodyn. 2019 Nov;38(8):2311-2317. doi: 10.1002/nau.24142. Epub 2019 Aug 20.

PMID:
31432572
10.

Evaluation of Preoperative Abdominal Adipose Tissue-, Inflammation-, Muscle Mass-, and Nutritional Status-based Prognostic Markers to Assess Renal Dysfunction in Living Kidney Donors.

Hori S, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Miyake M, Anai S, Torimoto K, Aoki K, Yoneda T, Tanaka N, Yoshida K, Fujimoto K.

Transplant Proc. 2019 Jul - Aug;51(6):1706-1716. doi: 10.1016/j.transproceed.2019.04.057.

PMID:
31399161
11.

Significant lack of urine-based biomarkers to replace cystoscopy for the surveillance of non-muscle invasive bladder cancer.

Miyake M, Owari T, Hori S, Fujimoto K.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S332-S334. doi: 10.21037/tau.2019.05.07. No abstract available.

12.

Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.

Miyake M, Hori S, Ohnishi S, Toritsuka M, Fujii T, Shimizu T, Owari T, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Anai S, Torimoto K, Tanaka N, Fujimoto K.

Cancer Sci. 2019 Oct;110(10):3315-3327. doi: 10.1111/cas.14158. Epub 2019 Aug 19.

13.

The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions.

Miyake M, Tanaka N, Asakawa I, Owari T, Hori S, Morizawa Y, Nakai Y, Inoue T, Anai S, Torimoto K, Hasegawa M, Fujii T, Konishi N, Fujimoto K.

Prostate Int. 2019 Jun;7(2):47-53. doi: 10.1016/j.prnil.2018.04.005. Epub 2018 May 5.

14.

Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study.

Kadono Y, Konaka H, Izumi K, Anai S, Fujimoto K, Ishibashi K, Kawai N, Kato T, Iba A, Masumori N, Yoshimura K, Mizokami A.

Contemp Clin Trials Commun. 2019 Jun 26;15:100403. doi: 10.1016/j.conctc.2019.100403. eCollection 2019 Sep.

15.

The Preoperative Predictive Factors for Pathological T3a Upstaging of Clinical T1 Renal Cell Carcinoma.

Fukui S, Miyake M, Iida K, Onishi K, Hori S, Morizawa Y, Kagebayashi Y, Fujimoto K.

Diagnostics (Basel). 2019 Jul 15;9(3). pii: E76. doi: 10.3390/diagnostics9030076.

16.

Clinical Significance of Postoperative Nutritional Status as a Prognostic Factor in Kidney Transplant Recipients.

Hori S, Ichikawa K, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Miyake M, Yoneda T, Tanaka N, Yoshida K, Fujimoto K.

Transplant Proc. 2019 Jul - Aug;51(6):1763-1772. doi: 10.1016/j.transproceed.2019.04.047. Epub 2019 Jun 27.

PMID:
31255359
17.

Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Guérin.

Miyake M, Hori S, Ohnishi S, Owari T, Iida K, Ohnishi K, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Fujii T, Tanaka N, Fujimoto K.

Diseases. 2019 Jun 18;7(2). pii: E44. doi: 10.3390/diseases7020044.

18.

Tadalafil, a phosphodiesterase type 5 inhibitor, restores urethra and detrusor function in the initial phase of diabetes in rats.

Gotoh D, Torimoto K, Iwasaki H, Iwamoto T, Morizawa Y, Hori S, Miyake M, Tanaka N, Hirayama A, Nishi E, Fujimoto K.

Low Urin Tract Symptoms. 2019 Sep;11(4):241-247. doi: 10.1111/luts.12272. Epub 2019 Jun 17.

PMID:
31207119
19.

Evaluation of pro‑ and anti‑tumor effects induced by three colony‑stimulating factors, G‑CSF, GM‑CSF and M‑CSF, in bladder cancer cells: Is G‑CSF a friend of bladder cancer cells?

Hori S, Miyake M, Onishi S, Morizawa Y, Nakai Y, Tatsumi Y, Onishi K, Iida K, Gotoh D, Itami Y, Tanaka N, Fujimoto K.

Int J Oncol. 2019 Jun;54(6):2237-2249. doi: 10.3892/ijo.2019.4772. Epub 2019 Apr 4.

PMID:
31081057
20.

Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.

Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y.

Int J Urol. 2019 Aug;26(8):797-803. doi: 10.1111/iju.14009. Epub 2019 May 5.

PMID:
31055879

Supplemental Content

Loading ...
Support Center